Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

被引:34
|
作者
Muayqil, Taim [1 ]
Camicioli, Richard [2 ]
机构
[1] King Saud Univ, Div Neurol, Riyadh, Saudi Arabia
[2] Univ Alberta, Div Neurol, Edmonton, AB, Canada
来源
关键词
Dementia; Alzheimer; Dementia therapy; Combination treatment; Cholinesterase inhibitors; Memantine; Side effects;
D O I
10.1159/000343479
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination. Objective: To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI. Methods: In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded ran-domized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes. Results: Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit. Conclusion: Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:546 / 572
页数:27
相关论文
共 50 条
  • [1] Important Error in 'Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias' by Muayqil and Camicioli
    Tariot, Pierre N.
    Wirth, Yvonne
    Graham, Stephen M.
    Tocco, Michael
    Fokkens, Jasmine
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2014, 4 (02): : 122 - 124
  • [2] Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Matsunaga, Shinji
    Kishi, Taro
    Iwata, Nakao
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (05): : 1 - 11
  • [3] Important Error in 'Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias' by Muayqil and Camicioli Reply
    Muayqil, Taim
    Camicioli, Richard
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2014, 4 (02): : 125 - 130
  • [4] Systematic review and meta-analysis of cholinesterase inhibitors and memantine for moderate to severe Alzheimer's disease
    Schneider, Lon S.
    Dagerman, Karen
    Shaikh, Zakaria
    McShane, Rupert
    [J]. NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S71 - S71
  • [5] Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
    Farrimond, Lucy E.
    Roberts, Emmert
    McShane, Rupert
    [J]. BMJ OPEN, 2012, 2 (03):
  • [6] Efficacy of cholinesterase inhibitors and memantine in Alzheimer's disease: a meta-analysis
    Kani, C.
    Papanikolaou, K.
    Pehlivanidis, A.
    Papadopoulou-Daifoti, Z.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S505 - S506
  • [7] Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Matsunaga, Shinji
    Kishi, Taro
    Iwata, Nakao
    [J]. PLOS ONE, 2015, 10 (04):
  • [8] Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis
    Kishi, Taro
    Matsunaga, Shinji
    Oya, Kazuto
    Nomura, Ikuo
    Ikuta, Toshikazu
    Iwata, Nakao
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (02) : 401 - 425
  • [9] Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-analysis
    Matsunaga, Shinji
    Kishi, Taro
    Iwata, Nakao
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 264 - 264
  • [10] Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis
    Pagano, Gennaro
    Rengo, Giuseppe
    Pasqualetti, Giuseppe
    Femminella, Grazia Daniela
    Monzani, Fabio
    Ferrara, Nicola
    Tagliati, Michele
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (07): : 767 - 773